Form 4: TransMedics Group CEO Waleed Hassanein Executes Option and Sells Shares

Sentiment:

SEC Form 4 Filing


TransMedics Group's CEO, Waleed H. Hassanein, exercised stock options and sold shares on July 15, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

  • On July 15, 2024, Waleed H. Hassanein, the President and CEO of TransMedics Group, Inc., exercised stock options to acquire 8,625 shares of common stock at a price of $13.28 per share.
  • Simultaneously, Hassanein sold a total of 8,625 shares of common stock in multiple transactions at weighted average prices ranging from $143.61 to $147.28.
  • These transactions were executed under a pre-arranged Rule 10b5-1 trading plan established on September 6, 2023.
  • Following these transactions, Hassanein directly owns 61,643 shares of TransMedics Group, Inc. common stock and indirectly owns 469,359 shares through the Waleed H. Hassanein Revocable Trust.
  • He also holds options to purchase 122,125 shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it reflects routine insider trading activity under a pre-existing plan. It doesn't inherently indicate positive or negative sentiment towards the company's prospects.

Industry Context

This filing is a routine disclosure of insider transactions and doesn't necessarily indicate a change in the company's outlook or performance. Insider selling can be driven by various personal financial planning reasons.

Key Dates

DateDescription
09/06/2023Date of entry into Rule 10b5-1 trading plan
07/15/2024Date of stock option exercise and share sales
02/22/2026Date the stock options are fully vested
02/22/2032Expiration date of the stock options
07/17/2024Date of Form 4 filing

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.